TickerTalks
Browse all tickers →
TickerTalks›$VKTX
VKVKTX

Viking Therapeutics, Inc.

$VKTX·$3.5B·Biotechnology·Healthcare
$25.17-8.0%YTD+17.2%1Y-27.5%
Price updated 7h ago·X counts updated 5d ago
VKVKTX
$VKTXViking Therapeutics, Inc.
$25.17-8.04%698 posts1×
AI analysisFundamentalsVoices on X
Loading…

On X

Top X posts

The complete picture of $VKTX on X — how loud the conversation is right now, how it has trended over the last two weeks, and which way the crowd is leaning.

698X posts · last 7 days
Sep 29Oct 11
Chatter Meter
1×
QuietNormal · 1×Loud

How loud $VKTX's conversation on X is versus its own normal — 1× is typical, higher means busier. Right now it's about its usual level.

Mixed sentimentAI analysisGenerated by AI from underlying data9 posts analyzed · as of 2026-10-02

Sentiment is complicated — bulls point to a 17.5mg VK2735 reading at week 33 already exceeding reta's week-80 benchmark, a plausible M&A base case within three months of Phase 3 (Oct-Nov 2027), and Petrelintide's "up to $10.6B" post-Phase-2 valuation as the floor. The sober longs admit this is a 2030s profit story. The pointed bear voice is a flat "VKTX to zero first, followed by NKTR and ABVX," leaving the room directionally split.

Read what X is saying about $VKTX

  • Bullish vs bearish call — with the AI summary of the day's posts
  • Divergence flag when the top-engagement posts argue the other side
  • How loud the conversation is versus this ticker's own normal
Free, forever. No credit card.

AI verdictAI analysisGenerated by AI from underlying data

TickerTalks' own read on what's driving $VKTX — fundamentals, momentum, or an event — and whether it agrees with the X crowd.

Hinges on a big eventCooling offAI verdict · as of 2026-10-03

Catching its breath after a run — could pick back up or fade from here.

A credible GLP-1-plus-amylin obesity play with real Phase 2 data and M&A optionality, now digesting a $500M capital raise.

Viking Therapeutics is a clinical-stage biotech chasing GLP-1-plus-amylin obesity drugs — lead candidate VK2735 is a differentiated shot at taking share from Novo and Lilly. It's a 2030s profit story and the market pays for that in volatility.

  • The clinical data has credibility: a 17.5mg Phase 2 readout showed weight loss already exceeding reta's week-80 benchmark by week 33 — the kind of print that keeps M&A optionality alive, with Novo publicly open to acquisitions.
  • They just raised $500M: $275M stock at $35 plus a $225M convertible — enough runway to carry VK2735 through Phase 3, but the stock now trades at $29.94, well below the offer price with the overhang still clearing.
  • Zero revenue and no commercial launch until decade's end means every move is binary on readouts — the current drawdown is pricing in dilution, not a thesis break.

Phase 3 start timing is the clock that matters, with M&A as free optionality. A missed primary endpoint on VK2735 and the equity is a donut.

Agrees with X sentimentX is split and reasonably so — the bulls on the 17.5mg maintenance data and the M&A base case are right that Phase 2 is genuinely competitive; the "VKTX to zero first" bears overstate but correctly see that pre-revenue biotech plus fresh $500M dilution is a brittle setup.

What to watch: Oct 28 Q3 earnings for cash runway and Phase 3 start date — a confirmed late-2026 or early-2027 initiation keeps M&A optionality live. Any safety signal or missed primary endpoint on a VK2735 readout is the hard break.

On the calendar: 2026-10-28 — Q3 2026 earnings

Read the AI verdict on $VKTX

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • Whether TickerTalks' read agrees with or diverges from the X crowd
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Develops GLP-1/GIP receptor agonists for obesity and NASH in both subcutaneous and oral formulations.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $VKTX.

Biotechnology · Healthcare

No material change from last week — mRNA oncology platform remains the structural driver.

What this means for $VKTX

Neutral — Develops GLP-1/GIP receptor agonists for obesity and NASH in both subcutaneous and oral formulations.

Top industry ETF

$IBBiShares Biotechnology ETF
+17.9%YTD
+31.7%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-7.0How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-100%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
0.0%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-10.3%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
0.0Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-71.3%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
0.0%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.0Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Jul 29, 2026$-1.10$-1.23+10.6%
Q1 2026Apr 29, 2026$-1.37$-1.01-35.6%
Q4 2025Feb 11, 2026$-1.38$-0.89-55.1%
Q3 2025Oct 22, 2025$-0.81$-0.70-15.7%
Next earningsWed, Oct 28·consensus EPS $-1.06

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$0———$-1.37$-114.0M
Q4 FY25$0———$-1.38$-85.3M
Q3 FY25$0———$-0.81$-94.0M
Q2 FY25$0———$-0.58$-47.1M

Forward consensus

5-year forecast · up to 16 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$7.2M$7.2M – $7.2M-$4.61-$5.52 – -$3.9310
FY27$7.3M$7.3M – $7.3M-$4.39-$6.50 – -$2.4011
FY28$174.0M$174.0M – $174.0M-$3.66-$6.40 – -$0.5816
FY29$474.4M$474.4M – $474.4M-$1.43-$1.43 – -$1.4314
FY30$1.2B$1.2B – $1.2B$2.28$2.28 – $2.2814

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.1.0×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.1%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-21.8%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.-23.2%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatMid float · 113.7M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today6.7% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β0.655-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.FilingActive offeringA shelf registration (S-3 / S-3ASR / S-1) or prospectus supplement (424B*) was filed in the last 90 days — the company is registered to (or actively) issuing new shares. Dilution risk.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellJul 29Brian LianCEO148.5K sh$4.9MSellJul 29Greg ZanteCFO21.2K sh$710KSellJul 29Marianna ManciniCOO18.2K sh$610K
+ 5 other (5 awards) in window

See when $VKTX insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KMaterial agreementSep 288-K — Item 1.01: Material agreement · Item 2.03: Material debt obligation
AI summary

Viking Therapeutics, Inc. (VKTX) entered into a material definitive agreement (8-K Item 1.01) filed on 2026-09-28. Also filed under: creation of direct financial obligation. The excerpt contains only the filing cover page; the full terms of the agreement are in the attached exhibit. Material definitive agreements are binding corporate commitments that can alter strategy, capital structure, or partnerships in ways that matter for equity holders.

424B5Prospectus supplement (offering)Sep 25424B5
AI summary

Viking Therapeutics (VKTX) priced $225 million of 2.00% Convertible Senior Notes due October 15, 2032, with a 30-day overallotment option for an additional $33.75 million, offered concurrently with a $275 million equity offering. The initial conversion rate is 19.7044 shares per $1,000 (~$50.75/share conversion price), a ~24% premium to VKTX's September 22 close of $40.85. Notes are redeemable at Viking's option on or after October 22, 2029. This is one leg of a dual-track ~$500 million capital raise, dilutive if converted but structured at a meaningful premium, presumably to fund VK2735 and pipeline development.

424B5Prospectus supplement (offering)Sep 25424B5
AI summary

Viking Therapeutics (VKTX) completed a fully underwritten public offering of 7,857,143 shares at $35.00/share for gross proceeds of ~$275 million (~$258.5 million net), concurrent with a $225 million convertible note offering; underwriters (Morgan Stanley, J.P. Morgan, Jefferies, Leerink, and others) hold a 30-day option for 1,178,571 additional shares. The $35.00 offer price represents a ~14% discount to the prior close of $40.85 on September 22, 2026. Shares were delivered September 25, 2026. This large dilutive equity raise—roughly 12% of pre-offering shares—was priced at a discount to fund clinical programs including VK2735.

424B5Prospectus supplement (offering)Sep 23424B5
AI summary

Viking Therapeutics (VKTX) filed a preliminary 424B5 prospectus supplement for convertible senior notes due 2032 on September 23, 2026; all material terms—interest rate, principal amount, conversion rate—are blank placeholders pending pricing. This preliminary filing was superseded by the final 424B5 (filed September 25, 2026) pricing the offering at $225 million at 2.00% with a ~$50.75/share conversion price. No independent action is required based on this preliminary document.

424B5Prospectus supplement (offering)Sep 23424B5
AI summary

Viking Therapeutics (VKTX) filed a preliminary 424B5 prospectus supplement for a common stock offering on September 23, 2026; all material terms—share count, offering price, proceeds—are blank placeholders pending pricing. This filing was superseded by the final 424B5 (filed September 25, 2026) pricing the offering at 7,857,143 shares at $35.00/share for gross proceeds of ~$275 million. No independent action is required based on this preliminary document.

3New insider — initial holdingsAug 73
AI summary

A reporting person filed an initial Form 3 at Viking Therapeutics (VKTX), disclosing no securities are beneficially owned — no common stock, options, or derivative securities. This is a routine initial Section 16 reporting obligation for a new insider or 10%-plus holder.

S-3ASRAuto-shelf registrationJul 30S-3ASR
AI summary

Viking Therapeutics, Inc. (VKTX) filed an automatic shelf registration (S-3ASR) as a large accelerated filer, registering securities for offerings from time to time, including a sales agreement prospectus for an ATM facility of up to $500 million of common stock through Stifel, Piper Sandler, Cantor Fitzgerald, and Oppenheimer. The shelf registration enables both primary issuances and selling shareholder resales. This is a standard capital markets flexibility tool; the $500M ATM represents potential dilution for Viking shareholders but is not an immediate offering.

3New insider — initial holdingsJun 33
AI summary

A new insider filed a Form 3 with the SEC, disclosing initial beneficial ownership of VKTX securities. This filing is required under Section 16(a) of the Securities Exchange Act within 10 days of becoming a reporting person (officer, director, or 10%+ holder). The filing reports 4 shares of common stock. Form 3 filings establish a baseline ownership record for subsequent Form 4 (changes) and Form 5 (annual) filings, providing transparency into insider positions at VKTX.

+ 8 other (2 10-Qs · 2 earnings 8-Ks · 1 305B2 · 1 routine 8-K) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Viking Therapeutics, Inc. (VKTX) Falls More Steeply Than Broader Market: What Investors Need to Knowzacks.com·9h agoViking Therapeutics Starts Phase III Development of Obesity Pillzacks.com·2d agoWall Street Bulls Look Optimistic About Viking Therapeutics (VKTX): Should You Buy?zacks.com·3d agoViking Therapeutics Announces Initiation of VK2735 Oral Phase 3 Clinical Program in Patients with Obesityprnewswire.com·3d ago3 Absurdly Cheap Stocks to Buy Before the End of 2026fool.com·3d ago

In themes

Explore the broader themes this ticker is being talked about under.

GLP-1 & Weight Loss

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$MRNA$ALEC$NWBO$DNA$NVAX$CAI$IBRX$RXRX
Voices on X · top 6 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport